| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.71B | 5.58 | 57.41 | 43.5% | 9.32% | 1.92% | ||
| CORTCorcept Therapeutics Incorporated | 3.72B | 35.39 | 28.77 | 39.94% | 14.19% | 16.65% | 5.26% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 302.14M | 1.97 | -1.22 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 465.15M | 1.28 | -2.03 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 260.56M | 2.81 | -2.87 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 172.89M | 2.03 | -3.03 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 442.41M | 4.24 | -3.16 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 771.24M | 21.51 | -3.24 | -12.81% | -27.32% | 0.03 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10M | 10M | 0 | 20.1M | 0 | 151K | 3.55M |
| Revenue Growth % | - | 0% | -1% | - | -1% | - | 22.51% |
| Cost of Goods Sold | 10.11M | 17.35M | 605K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 1.01% | 1.73% | - | - | - | - | - |
| Gross Profit | -111K | -7.35M | -605K | 20.1M | 0 | 151K | 3.55M |
| Gross Margin % | -0.01% | -0.73% | - | 1% | - | 1% | 1% |
| Gross Profit Growth % | - | -65.2% | 0.92% | 34.22% | -1% | - | 22.51% |
| Operating Expenses | 11.32M | 20M | 46.05M | 76.47M | 114.79M | 170.09M | 214.38M |
| OpEx % of Revenue | 1.13% | 2% | - | 3.8% | - | 1126.44% | 60.39% |
| Selling, General & Admin | 1.58M | 3.18M | 12.19M | 21.33M | 27.52M | 34.83M | 40.75M |
| SG&A % of Revenue | 0.16% | 0.32% | - | 1.06% | - | 230.69% | 11.48% |
| Research & Development | 10.11M | 17.38M | 33.86M | 55.14M | 87.27M | 135.26M | 173.63M |
| R&D % of Revenue | 1.01% | 1.74% | - | 2.74% | - | 895.75% | 48.91% |
| Other Operating Expenses | 237K | -558K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.69M | -10.56M | -46.66M | -56.37M | -114.79M | -169.94M | -210.83M |
| Operating Margin % | -0.17% | -1.06% | - | -2.8% | - | -1125.44% | -59.39% |
| Operating Income Growth % | - | -5.25% | -3.42% | -0.21% | -1.04% | -0.48% | -0.24% |
| EBITDA | -1.39M | -10.13M | -46.05M | -55.99M | -114.12M | -169.13M | -209.6M |
| EBITDA Margin % | -0.14% | -1.01% | - | -2.79% | - | -1120.04% | -59.04% |
| EBITDA Growth % | - | -6.3% | -3.55% | -0.22% | -1.04% | -0.48% | -0.24% |
| D&A (Non-Cash Add-back) | 304K | 438K | 605K | 378K | 674K | 815K | 1.23M |
| EBIT | -1.32M | -12.33M | -45.53M | -56.73M | -104.68M | -152.99M | -187.05M |
| Net Interest Income | 6K | -8K | 0 | -4K | 0 | 0 | 0 |
| Interest Income | 6K | 0 | 6K | 0 | 1K | 0 | 0 |
| Interest Expense | 0 | 8K | 6K | 4K | 1K | 0 | 0 |
| Other Income/Expense | 613K | -1.77M | 1.12M | -360K | 10.11M | 16.95M | 23.78M |
| Pretax Income | -1.08M | -12.34M | -45.53M | -56.73M | -104.68M | -152.99M | -187.05M |
| Pretax Margin % | -0.11% | -1.23% | - | -2.82% | - | -1013.19% | -52.69% |
| Income Tax | 257K | 0 | -172K | 2.01M | 0 | 0 | 300K |
| Effective Tax Rate % | 1.24% | 1% | 1% | 1.04% | 1% | 1% | 1% |
| Net Income | -1.33M | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M |
| Net Margin % | -0.13% | -1.23% | - | -2.92% | - | -1013.19% | -52.78% |
| Net Income Growth % | - | -8.25% | -2.67% | -0.3% | -0.78% | -0.46% | -0.22% |
| Net Income (Continuing) | -1.33M | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.15 | -1.39 | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 |
| EPS Growth % | - | -8.27% | -1.11% | 0.14% | -0.65% | -0.25% | 0.04% |
| EPS (Basic) | -0.15 | -1.39 | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 |
| Diluted Shares Outstanding | 8.88M | 8.88M | 15.51M | 23.33M | 25.24M | 29.45M | 37.44M |
| Basic Shares Outstanding | 8.88M | 8.88M | 15.51M | 23.33M | 25.24M | 29.45M | 37.44M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 25.53M | 8.93M | 267.73M | 251.44M | 285.77M | 347.29M | 588.89M |
| Cash & Short-Term Investments | 23.26M | 7.02M | 265.88M | 230.04M | 279.05M | 331.15M | 559.93M |
| Cash Only | 23.26M | 7.02M | 265.88M | 230.04M | 279.05M | 331.15M | 559.93M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 922K | 216K | 18.2M | 841K | 1.09M | 4.46M |
| Days Sales Outstanding | - | 33.65 | - | 330.44 | - | 2.64K | 458.15 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 84K | 819K | 160K | 210K | 276K | 1M | 1.48M |
| Total Non-Current Assets | 1.88M | 2.03M | 1.72M | 3.81M | 21.01M | 22.73M | 26.99M |
| Property, Plant & Equipment | 1.38M | 1.91M | 1.6M | 2.4M | 17.57M | 19.47M | 23.49M |
| Fixed Asset Turnover | 7.25x | 5.23x | - | 8.37x | - | 0.01x | 0.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 501K | 0 | 0 | 0 | 0 | 1.21M | 1.45M |
| Other Non-Current Assets | 0 | 115K | 115K | 1.41M | 3.44M | 2.05M | 2.06M |
| Total Assets | 27.41M | 10.96M | 269.44M | 255.25M | 306.78M | 370.02M | 615.89M |
| Asset Turnover | 0.36x | 0.91x | - | 0.08x | - | 0.00x | 0.01x |
| Asset Growth % | - | -0.6% | 23.6% | -0.05% | 0.2% | 0.21% | 0.66% |
| Total Current Liabilities | 11.47M | 4.49M | 7.18M | 11.85M | 16.55M | 24.37M | 27.45M |
| Accounts Payable | 501K | 2.09M | 2.15M | 3.65M | 3.34M | 5.45M | 4.6M |
| Days Payables Outstanding | 18.09 | 43.93 | 1.3K | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 477K | 1.02M | 1.73M | 2.58M | 5.56M | 10.38M | 10.55M |
| Current Ratio | 2.23x | 1.99x | 37.27x | 21.23x | 17.27x | 14.25x | 21.45x |
| Quick Ratio | 2.23x | 1.99x | 37.27x | 21.23x | 17.27x | 14.25x | 21.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.19M | 5.97M | 538K | 231K | 12.81M | 13.44M | 16.88M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 622K | 899K | 476K | 231K | 12.81M | 13.44M | 16.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.56M | 5.08M | 62K | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.65M | 10.46M | 7.72M | 12.08M | 29.36M | 37.81M | 44.33M |
| Total Debt | 788K | 1.27M | 899K | 1.09M | 13.27M | 14.44M | 18.86M |
| Net Debt | -22.47M | -5.75M | -264.98M | -228.95M | -265.78M | -316.7M | -541.07M |
| Debt / Equity | 0.06x | 2.58x | 0.00x | 0.00x | 0.05x | 0.04x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -1320.38x | -7776.17x | -14093.25x | -114790.00x | - | - |
| Total Equity | 12.76M | 495K | 261.72M | 243.17M | 277.42M | 332.21M | 571.55M |
| Equity Growth % | - | -0.96% | 527.73% | -0.07% | 0.14% | 0.2% | 0.72% |
| Book Value per Share | 1.44 | 0.06 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 |
| Total Shareholders' Equity | 12.76M | 495K | 261.72M | 243.17M | 277.42M | 332.21M | 571.55M |
| Common Stock | 1K | 1K | 2K | 2K | 2K | 3K | 4K |
| Retained Earnings | -7.31M | -19.65M | -65.01M | -123.75M | -228.43M | -381.43M | -568.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -246K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 7.04M | -16M | -36.89M | -62.15M | -70.06M | -124.51M | -160.87M |
| Operating CF Margin % | 0.7% | -1.6% | - | -3.09% | - | -824.56% | -45.32% |
| Operating CF Growth % | - | -3.27% | -1.31% | -0.68% | -0.13% | -0.78% | -0.29% |
| Net Income | -1.33M | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M |
| Depreciation & Amortization | 153K | 438K | 278K | 378K | 674K | 815K | 1.23M |
| Stock-Based Compensation | 81K | 0 | 4.1M | 11.72M | 18.68M | 28.76M | 34.87M |
| Deferred Taxes | 0 | 0 | 0 | 46K | 0 | 0 | 0 |
| Other Non-Cash Items | 194K | 2.62M | 1.82M | 520K | 953K | 1.56M | 1.82M |
| Working Capital Changes | 7.95M | -6.72M | 2.27M | -16.07M | 14.31M | -2.65M | -11.44M |
| Change in Receivables | -370K | -552K | 922K | -18M | 18M | -143K | -2.6M |
| Change in Inventory | 0 | 0 | -922K | 1.04M | 0 | -4.5M | 0 |
| Change in Payables | -2K | 1.31M | 61K | 1.49M | -408K | 1.61M | -249K |
| Cash from Investing | -217K | -271K | -294K | -1.02M | -1.24M | -2.46M | -1.93M |
| Capital Expenditures | -217K | -271K | -294K | -1.02M | -1.24M | -2.46M | -1.93M |
| CapEx % of Revenue | 0.02% | 0.03% | - | 0.05% | - | 16.32% | 0.54% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 11.46M | 14K | 296.04M | 28.55M | 120.31M | 178.96M | 391.82M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | -37K | 0 | -3.16M | 379K | 731K | 3.13M | 11.69M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | 6.83M | -16.27M | -37.19M | -63.17M | -71.3M | -126.97M | -162.8M |
| FCF Margin % | 0.68% | -1.63% | - | -3.14% | - | -840.87% | -45.86% |
| FCF Growth % | - | -3.38% | -1.29% | -0.7% | -0.13% | -0.78% | -0.28% |
| FCF per Share | 0.77 | -1.83 | -2.40 | -2.71 | -2.82 | -4.31 | -4.35 |
| FCF Conversion (FCF/Net Income) | -5.27x | 1.30x | 0.81x | 1.06x | 0.67x | 0.81x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -10.46% | -186.28% | -34.6% | -23.27% | -40.22% | -50.19% | -41.46% |
| Return on Invested Capital (ROIC) | - | - | - | -770.9% | -665.68% | -938.87% | -687.6% |
| Gross Margin | -1.11% | -73.48% | - | 100% | - | 100% | 100% |
| Net Margin | -13.35% | -123.44% | - | -292.26% | - | -101319.21% | -5277.55% |
| Debt / Equity | 0.06x | 2.58x | 0.00x | 0.00x | 0.05x | 0.04x | 0.03x |
| Interest Coverage | - | -1320.38x | -7776.17x | -14093.25x | -114790.00x | - | - |
| FCF Conversion | -5.27x | 1.30x | 0.81x | 1.06x | 0.67x | 0.81x | 0.86x |
| Revenue Growth | - | 0% | -100% | - | -100% | - | 2250.99% |
| 2021 | 2022 | 2024 | |
|---|---|---|---|
| License | 144M | 144M | 144M |
| License Growth | - | 0.00% | 0.00% |
| Service | - | - | 3M |
| Service Growth | - | - | - |
Keros Therapeutics, Inc. (KROS) reported $246.7M in revenue for fiscal year 2024. This represents a 2367% increase from $10.0M in 2018.
Keros Therapeutics, Inc. (KROS) grew revenue by 2251.0% over the past year. This is strong growth.
Yes, Keros Therapeutics, Inc. (KROS) is profitable, generating $64.4M in net income for fiscal year 2024 (-5277.5% net margin).
Keros Therapeutics, Inc. (KROS) has a return on equity (ROE) of -41.5%. Negative ROE indicates the company is unprofitable.
Keros Therapeutics, Inc. (KROS) generated $87.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.